Friday, February 23, 2024
Canada’s Politics and Government News Source Since 1989
Friday, February 23, 2024 | Latest Paper

Lisa M. Olson

Lisa M. Olson is vice-president, immunology discovery at AbbVie and site head at the AbbVie Bioresearch Center.

Opinion | BY LISA M. OLSON | November 20, 2019
While there has been tremendous progress in the treatment of rheumatoid arthritis over the past two decades, more than two-thirds of treated patients still do not achieve clinical remission or low disease activity treatment targets, writes Lisa M. Olson. Photograph courtesy of Adobe Stock/AbbVie Canada
Opinion | BY LISA M. OLSON | November 20, 2019
Opinion | BY LISA M. OLSON | November 20, 2019
While there has been tremendous progress in the treatment of rheumatoid arthritis over the past two decades, more than two-thirds of treated patients still do not achieve clinical remission or low disease activity treatment targets, writes Lisa M. Olson. Photograph courtesy of Adobe Stock/AbbVie Canada